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1 – Introduction 33 
Vascular calcification (VC) is a pathological deposition of calcium-salts in the vasculature 34 
and constitutes an independent risk factor for cardiovascular disease (CVD) and mortality [1]. 35 
Type 2 diabetes is characterized by a high prevalence of tibial artery calcification [2], which 36 
in conjunction with atherosclerosis contributes to peripheral artery occlusive disease with foot 37 
ulcers and needs for leg amputation. A better understanding of the pathological mechanisms 38 
involved in below-knee VC is necessary to develop new therapeutic strategies aimed to avoid 39 
or to delay this dramatic complication of type 2 diabetes. Disorders of bone and mineral 40 
metabolism has been shown to confer an increased risk of VC per se [3,4] suggesting a link 41 
between impaired bone mineralization and excessive mineral deposition in the arterial wall. 42 
Of note, both high and low turnover forms of bone disease have been associated with VC. 43 
Since bone turnover is frequently decreased in type 2 diabetes [5], we postulated the possible 44 
existence of an association between below-knee VC and bone and mineral metabolism in 45 
patients with type 2 diabetes.  46 
 47 
2 – Material and methods 48 
We recently reported the set-up of a cross-sectional study entitled DIACART (for “Diabète et 49 
Calcification Artérielle”) [6]. A total of 198 patients were recruited during an 8-month period. 50 
Inclusion criteria were type 2 diabetes and at least one of the following parameters: (i) 51 
coronary artery disease, (ii) peripheral arterial occlusive disease, and (iii) age > 50 or > 60 52 
years for men and women, respectively. Exclusion criteria were (i) an estimated glomerular 53 
filtration rate (eGFR) < 30 mL/min, as assessed by the modification of diet in renal disease 54 
equation, (ii) type 1 diabetes, and (iii) history of lower limb angioplasty or bypass. In these 55 
198 patients, we measured the circulating levels of the bone resorption marker carboxy-56 
terminal type I collagen cross-links (CTX-I), the bone formation marker bone alkaline 57 
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phosphatase (BAP) as well as the circulating level of mineral metabolism markers including 58 
total 25-hydroxy vitamin D [25(OH) vitD], intact parathyroid hormone (iPTH), fibroblast 59 
growth factor 23 (FGF-23) and α-klotho. Below-knee artery calcification scoring was 60 
calculated after imaging with a 128-slice multidetector CT scanner (Somatom Definition 61 
Flash, Siemens Healthcare, Forchheim, Germany) in tibial region. An overall calcification 62 
score expressed in Agatston Units (AU) was calculated by adding the calcification scores of 63 
the main below-knee arteries, i.e. distal popliteal, anterior tibial, posterior tibial, and peroneal 64 
arteries (6).  65 
Data are expressed as mean ± standard deviation (median) for quantitative variables, and as 66 
frequency for qualitative variables, as appropriate. To describe the study population, patients 67 
were divided according to tertile groups for below-knee artery calcification scores, and 68 
presence or absence of biochemical hyperparathyroidism, as determined by the usual 69 
threshold of a serum iPTH level ≥ 65pg/mL. Comparisons between tertile groups of 70 
calcification were performed with ANOVA followed by Tukey post-test or with χ² test 71 
followed by χ² post-test with Bonferroni correction. Comparisons between patients with or 72 
without biochemical hyperparathyroidism were performed with χ ² test for qualitative 73 
variables and Student’s t test or Mann Whitney test for continuous variables. Univariate 74 
logistic regression analyses were used to assess the association between scores of below-knee 75 
calcification and demographic, biochemical and clinical variables. Multivariable logistic 76 
regression was performed by including parameters that were identified in univariate analyses 77 
with p < 0.10. 78 
 79 
3 – Results 80 
In the population studied, the proportion of men and women was 80% and 20% respectively, 81 
mean age 64.4 years and mean estimated of duration of type 2 diabetes 14.6 years. Previous 82 
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CVD was recorded in 70% of the patients, and 82% had a diagnosis of arterial hypertension. 83 
History or active tobacco use was found in 119 patients (60%). Mean eGFR of the population 84 
was 76 ± 20 mL/min. The tertile groups for below-knee artery calcification scores were 85 
respectively low calcification (≤166 UA), intermediate calcification (167-1614 UA), and high 86 
calcification score (>1614 UA). Those with higher below-knee artery calcification scores 87 
tended to be of male gender and older age, to have lower eGFR, and to have more frequently 88 
CVD and neuropathy. Among the biochemical markers of bone turnover and mineral 89 
metabolism, only serum iPTH concentrations were significantly different between the three 90 
subgroups: 60.8 ± 30.7 and 57.6 ± 29.8 pg/mL in second and third tertiles with intermediate 91 
and high calcification scores versus 45.5 ± 18 pg/mL in first tertile with low calcification 92 
score (p = 0.003). The mean 25(OH) vitD concentration for the whole population (13.8 ± 8.4 93 
ng/mL) was in the range reflecting vitamin D moderate deficiency [25(OH) vitD between 10 94 
and 20 ng/mL [7]], and the mean CTX-I concentration (0.140 ± 0.133 ng/mL) was close to 95 
the lower limit of normal values for the assay kit used. Mean FGF-23 (27.4 ± 29.2 RU/mL) 96 
and α-klotho (826 ± 260 pg/mL) were also in the range of the usual values for the respective 97 
assays. Univariate logistic regression analysis corroborated that among bone and mineral 98 
markers, only higher iPTH values were associated with calcification scores greater than 166 99 
(Figure 1A). The other variables significantly associated with higher calcification scores were 100 
age, male gender, previous CVD, tobacco use, retinopathy, and lower eGFR. When these 101 
variables were included in a multivariable analysis, serum iPTH remained independently 102 
associated with below-knee artery calcification scores (OR per 10 pg/mL increment: 1.26; 103 
95% CI 1.09 – 1.45; p = 0.035, Figure 1B). When we studied the characteristics of the 104 
population according to biochemical hyperparathyroidism, we showed that in patients with 105 
iPTH values ≥ 65 pg/mL, serum 25(OH) vitD was significantly lower as compared to those 106 
with iPTH < 65 pg/mL (10.2 ± 6.8 ng/mL versus 15.0 ± 8.6 ng/mL; p<0.001). Interestingly, 107 
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vitamin D deficiency (defined by 25(OH) vitD levels ≤ 10 ng/mL) was more frequently 108 
observed in patients with biochemical hyperparathyroidism (62.5% versus 28.9%; p = 0.023). 109 
 110 
4 – Discussion 111 
In the present work, we found that in patients with type 2 diabetes and high cardiovascular 112 
risk but no severe CKD, serum iPTH was significantly and independently associated with 113 
below-knee arterial calcification score. None of the other studied biochemical markers of 114 
bone and mineral metabolism was associated with calcification. In the general population [8] 115 
as well as in type 2 diabetes [9], it has been demonstrated that high plasma iPTH levels are 116 
independently associated with higher cardiovascular mortality risk. Our finding demonstrating 117 
an association between PTH and VC, suggests that PTH may contribute to CVD in type 2 118 
diabetes through the development of VC. The mechanisms whereby PTH could contribute to 119 
VC and CVD in patients with normal or moderately altered kidney function are not clearly 120 
known. Secretion of PTH from parathyroid gland is triggered by low serum calcium, which in 121 
turn raises serum calcium through its decrease in renal excretion and its release from bone. 122 
Thus, one possible mechanism for the contribution of PTH to VC is an increase in bone 123 
turnover leading to a high serum calcium x phosphate product. In our study, while the mean 124 
serum BAP concentration was similar to that observed in men and post-menopausal women in 125 
the general population, mean serum CTX-I values were about two-fold lower, in line with the 126 
notion that type 2 diabetes is a state of low bone turnover [5]. Although influenced by PTH 127 
status, bone resorption level is rather low and seems not to impact below-knee VC. A 128 
disturbance of the FGF-23/αklotho axis could be another factor affecting both VC and bone 129 
mineralization [10]. In the present study, FGF-23 and α-klotho concentrations were in the 130 
range given by the manufacturer of the assay kits used and didn't associate with VC. Serum 131 
iPTH has been associated with progression of vascular or valvular calcifications in secondary 132 
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hyperparathyroidism due to CKD [11], in elderly patients without severe CKD [12] and in 133 
mild primary hyperparathyroidism [13]. Finally, a very recent study demonstrated in type 1 134 
diabetes an association of higher PTH levels with increased arterial stiffness, which is a 135 
consequence of VC [14]. Taken together, these results and ours seem to support the view that 136 
biochemical hyperparathyroidism might accelerate the progression of VC in type 2 diabetes. 137 
As expected, in our study there was a significant relationship between serum iPTH and 138 
25(OH) vitD. More than 60% of our patients with biochemical hyperparathyroidism presented 139 
severe vitamin D deficiency whereas only 3% of the total population received vitamin D 140 
supplementation. This high prevalence of vitamin D deficiency in type 2 diabetes should be 141 
given careful consideration, all the more since 25(OH) vitD was also found to be associated 142 
with micro- and macrovascular complications [15]. As vitamin D supplementation can 143 
quickly restore serum 25(OH) vitD concentration and reduce PTH levels, vitamin D 144 
supplementation could represent a therapeutic option to delay VC induced by 145 
hyperparathyroidism.  146 
The strengths of the present study are the assessment of a below-knee artery calcification 147 
score by high-sensitivity CT scan and the simultaneous measurement of numerous parameters 148 
of bone and mineral metabolism. The study would have been strengthened by the 149 
measurement of circulating biomarkers in a healthy control group.  150 
 151 
6 – Conclusion 152 
In conclusion, we found that among circulating markers of bone and mineral metabolism, 153 
only serum iPTH levels was independently associated with below-knee artery calcification 154 
score in patients with type 2 diabetes. Increased iPTH values were related to severe vitamin D 155 
deficiency. Whether the avoidance of mild hyperparathyroidism by vitamin D 156 
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supplementation can prevent or retard lower limb vascular calcification in type 2 diabetes 157 
patients remains to be assessed in prospective randomized trials.  158 
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FIGURE LEGEND 217 
Figure 1: Association of below-knee artery calcification score with markers of bone and 218 
mineral metabolism (n=198). A. Odds ratio [95%CI] for each marker of bone and mineral 219 
metabolism was analysed by univariate logistic regression. B. Odds ratio [95%CI] for each 220 
variable was analysed by multivariable logistic regression. Only variables significantly 221 
associated with VC in univariate analyses were included in the multivariable model. 222 
Abbreviations: iPTH: intact parathyroid hormone; FGF-23: fibroblast growth factor; 25(OH) 223 
vitD: 25-hydroxyvitamin D; CTX-I: carboxy-terminal type I collagen crosslinks; BAP: bone-224 
specific alkaline phosphatase; CVD: cardiovascular disease; eGFR: glomerular filtration rate. 225 
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